Alkermes to Participate in Two Upcoming Investor Conferences
Alkermes plc (Nasdaq: ALKS) has announced its participation in two upcoming investor conferences in November 2024. The company will present at the Stifel Healthcare Conference on November 18 at 8:35 a.m. ET and the Jefferies London Healthcare Conference on November 19 at 8:00 a.m. ET. Live webcasts will be available on Alkermes' website under the Investors tab and archived for 14 days.
Alkermes is a global biopharmaceutical company focused on neuroscience, with commercial products for alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. The company maintains operations in Ireland, Massachusetts, and Ohio.
Alkermes plc (Nasdaq: ALKS) ha annunciato la sua partecipazione a due conferenze per investitori in programma a novembre 2024. L'azienda presenterà alla Stifel Healthcare Conference il 18 novembre alle 8:35 a.m. ET e alla Jefferies London Healthcare Conference il 19 novembre alle 8:00 a.m. ET. Saranno disponibili webcasts in diretta sul sito web di Alkermes sotto la scheda Investitori e archiviati per 14 giorni.
Alkermes è una azienda biofarmaceutica globale concentrata sulle neuroscienze, con prodotti commerciali per la dipendenza da alcol, la dipendenza da oppioidi, la schizofrenia e il disturbo bipolare di tipo I. L'azienda mantiene operazioni in Irlanda, Massachusetts e Ohio.
Alkermes plc (Nasdaq: ALKS) ha anunciado su participación en dos próximas conferencias para inversores en noviembre de 2024. La empresa presentará en la Stifel Healthcare Conference el 18 de noviembre a las 8:35 a.m. ET y en la Jefferies London Healthcare Conference el 19 de noviembre a las 8:00 a.m. ET. Se podrán ver transmisiones en vivo en el sitio web de Alkermes en la pestaña de Inversores y estarán archivadas durante 14 días.
Alkermes es una empresa biofarmacéutica global centrada en la neurociencia, con productos comerciales para la dependencia del alcohol, la dependencia de opioides, la esquizofrenia y el trastorno bipolar tipo I. La empresa tiene operaciones en Irlanda, Massachusetts y Ohio.
알케르메스 plc (Nasdaq: ALKS)는 2024년 11월에 있을 두 개의 투자자 컨퍼런스에 참여할 것이라고 발표했습니다. 이 회사는 11월 18일 오전 8시 35분 ET에 Stifel Healthcare Conference에서 발표하고, 11월 19일 오전 8시 00분 ET에 Jefferies London Healthcare Conference에서 발표할 예정입니다. Alkermes의 웹사이트 투자자 탭에서 생중계를 시청할 수 있으며, 14일 동안 아카이브됩니다.
Alkermes는 신경과학에 중점을 두고 있는 글로벌 생물제약 회사로, 알코올 의존증, 오피오이드 의존증, 정신분열증 및 양극성 장애 I형에 대한 상용 제품을 보유하고 있습니다. 이 회사는 아일랜드, 매사추세츠, 오하이오에서 운영되고 있습니다.
Alkermes plc (Nasdaq: ALKS) a annoncé sa participation à deux conférences d'investisseurs à venir en novembre 2024. La société présentera à la Stifel Healthcare Conference le 18 novembre à 8h35 ET et à la Jefferies London Healthcare Conference le 19 novembre à 8h00 ET. Des webdiffusions en direct seront disponibles sur le site web d'Alkermes sous la section Investisseurs et archivées pendant 14 jours.
Alkermes est une entreprise biopharmaceutique mondiale axée sur les neurosciences, avec des produits commerciaux pour la dépendance à l'alcool, la dépendance aux opioïdes, la schizophrénie et le trouble bipolaire de type I. L'entreprise a des opérations en Irlande, dans le Massachusetts et dans l'Ohio.
Alkermes plc (Nasdaq: ALKS) hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im November 2024 bekannt gegeben. Das Unternehmen wird am 18. November um 8:35 Uhr ET auf der Stifel Healthcare Conference und am 19. November um 8:00 Uhr ET auf der Jefferies London Healthcare Conference präsentieren. Live-Webcasts werden auf der Website von Alkermes unter dem Tab Investoren verfügbar sein und für 14 Tage archiviert.
Alkermes ist ein globales biopharmazeutisches Unternehmen, das sich auf Neurowissenschaften konzentriert und kommerzielle Produkte für Alkoholabhängigkeit, Opioidabhängigkeit, Schizophrenie und Bipolar-I-Störung anbietet. Das Unternehmen hat Standorte in Irland, Massachusetts und Ohio.
- None.
- None.
Stifel Healthcare Conference
Date/Time: Monday, Nov. 18, 2024 at 8:35 a.m. ET (1:35 p.m. GMT)
Jefferies London Healthcare Conference
Date/Time: Tuesday, Nov. 19, 2024 at 8:00 a.m. ET (1:00 p.m. GMT)
The live webcasts may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
About Alkermes plc
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in
Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402
View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-participate-in-two-upcoming-investor-conferences-302301608.html
SOURCE Alkermes plc
FAQ
When is Alkermes (ALKS) presenting at the Stifel Healthcare Conference in 2024?
What time is Alkermes (ALKS) presenting at the Jefferies London Healthcare Conference?
How long will Alkermes (ALKS) investor conference webcasts be available?
What therapeutic areas does Alkermes (ALKS) focus on?
